Pharmacokinetics of Intravitreally Injected Bevacizumab in Vitrectomized Eyes

Journal of Ocular Pharmacology and Therapeutics - United States
doi 10.1089/jop.2013.0009
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Mary Ann Liebert Inc

Related search

Biometric Parameters of Vitrectomized Eyes

Vestnik Oftalmologii
MedicineOphthalmology
2016English

Structural and Functional Characteristics of Vitrectomized Eyes

Vestnik Oftalmologii
MedicineOphthalmology
2016English

Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes

Investigative Ophthalmology and Visual Science
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2015English

MR‐Imaging Enables Accurate Diagnosis and Follow‐up for Vitrectomized Eyes in Uveal Melanoma Patients

Acta Ophthalmologica
MedicineOphthalmology
2018English

Systemic Pharmacokinetics and Pharmacodynamics of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab

Retina
MedicineOphthalmology
2017English

Effect of Intravitreal Triamcinolone Acetonide or Bevacizumab on Choroidal Thickness in Eyes With Diabetic Macular Edema

Investigative Ophthalmology and Visual Science
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2014English

Posterior Vitreous Detachment With Microplasmin Alters the Retinal Penetration of Intravitreal Bevacizumab (Avastin) in Rabbit Eyes

Retina
MedicineOphthalmology
2011English

Ocular Pharmacokinetics of Bimatoprost Formulated in DuraSite Compared to Bimatoprost 0.03% Ophthalmic Solution in Pigmented Rabbit Eyes

Clinical Ophthalmology
Ophthalmology
2013English

Allometric Considerations on Proteins Administered Intravitreally to Children

CPT: Pharmacometrics and Systems Pharmacology
ModelingSimulationCardiovascular MedicinePharmacologyCardiology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy